Point72 Hong Kong LTD Amicus Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $133,561 - $173,412	13,601 New	13,601 $142,000
Q2 2022 Aug 15, 2022	SELL	$6.23 - $11.12 $79,027 - $141,057	-12,685 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.89 - $12.48 $12,986 - $20,542	1,646 Added 14.91%	12,685 $120,000
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $66,776 - $84,592	-6,800 Reduced 38.12%	11,039 $128,000
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $105,701 - $143,192	12,094 Added 210.51%	17,839 $170,000
Q2 2021 Aug 16, 2021	BUY	$8.71 - $10.72 $50,038 - $61,586	5,745 New	5,745 $55,000
Q1 2021 May 17, 2021	SELL	$9.2 - $23.86 $2,235 - $5,797	-243 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.47 - $24.89 $3,273 - $6,048	243 New	243 $6,000
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $12,138 - $21,495	-1,370 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.63 - $11.16 $8,784 - $14,787	1,325 Added 2944.44%	1,370 $13,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $10.75 $11,436 - $16,436	-1,529 Reduced 97.14%	45 $0
Q3 2019 Nov 14, 2019	SELL	$8.02 - $13.25 $18,702 - $30,899	-2,332 Reduced 59.7%	1,574 $13,000
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $42,809 - $56,246	3,906 New	3,906 $49,000
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $592 - $821	-59 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$8.38 - $13.44 $24,972 - $40,051	-2,980 Reduced 98.06%	59 $1,000
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $32,340 - $46,113	2,788 Added 1110.76%	3,039 $37,000
Q2 2018 Aug 14, 2018	BUY	$13.13 - $17.09 $3,295 - $4,289	251 New	251 $4,000

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.